OBJECTIVES: To evaluate the cost-effectiveness of prescribing branded Taxotere®compared to its generic counterpart docetaxel for patients diagnosed with breast cancer in the UK NHS. METHODS: A previously published decision tree model was populated and developed with the Vial et. al. and Brown et. al. trial data to assess the cost-effectiveness of using branded Taxotere®versus its generic counterpart docetaxel from the UK NHS perspective. RESULTS: If the branded Taxotere® was promoted as the first-line therapy, it would cost the UK NHS £411.54 per vial per patient with 0.434 QALY gain compared to £412.98 with 0.418 QALY gain if the generic docetaxel was promoted instead and failed the therapy. Although the acquisition cost of docetaxel is more than 50% less than that of Taxotere®, promoting the generic docetaxel based on its lower acquisition cost, only, would result in increasing the total healthcare cost compared to Taxotere®. CONCLUSIONS: Based on the decision tree model generated in this study, promoting the branded Taxotere® is more cost-effective compared to its generic counterpart docetaxel. This should be considered for implementation in practice and for future guidelines.